| DC74945 |
Meclizine Dihydrochloride |
Meclizine dihydrochloride is a histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness. Meclizine hydrochloride increases human pregnane X receptor (hPXR) target gene expression in human hepatocyte primary cultures. |
|
| DC74946 |
Bemnifosbuvir free base |
AT-511 is a prodrug form of the antiviral nucleoside analog AT-9010. It reduces the infectious virus yield in cells infected with Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome CoV (SARS-CoV), SARS-CoV-2, human CoV 229E (HCoV-229E), and HCoV-OC43 (EC90s = 37, 0.47, 2.8, 1.2, and 0.5 µM, respectively). AT-527 is the sulfate salt of AT-511. |
|
| DC74947 |
Naloxegol Oxalate |
Naloxegol, also known as and NKTR-118 and AZ-13337019, is a peripherally-selective opioid antagonist for the treatment of opioid-induced constipation. It was approved in 2014 in adult patients with chronic, non-cancer pain. Chemically, naloxegol is a pegylated (polyethylene glycol-modified) derivative of α-naloxol. Specifically, the 5-α-hydroxyl group of α-naloxol is connected via an ether linkage to the free hydroxyl group of a monomethoxy-terminated n=7 oligomer of PEG. |
|
| DC74948 |
OUN10989 |
OUN10989, an analogue compound of LP-261, is a Potent Antimitotic Agent. OUN10989 exhibited potent inhibition of mitosis at the G2/M stage. OUN10989 was first reported in J. Med. Chem 54(1), 179-200; 2011 (compound 7). This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming). |
|
| DC74949 |
Elimusertib free base |
Elimusertib, also known as BAY-1895344, is a potent and selective ATM inhibitor. BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride. |
|
| DC74950 |
MK-571 sodium |
MK-571 is a selective, orally active CysLT1 receptor antagonist. It blocks the binding of LTD4, but not LTC4, to human and guinea pig lung membranes with Ki values of 0.22 nM and 2.1 nM, respectively. MK-571 attenuates kidney ischemia and reperfusion-induced airway hypersensitivity in rats. MK-571 alters bronchoalveolar lavage fluid proteome in a mouse asthma model. |
|
| DC74951 |
Butantrone |
Butantrone is the 10-butyryl derivative of dithranol with antipsoriatic activity. When butantrone and dithranol were used in equimolar gradually increasing concentrations in short-contact therapy for psoriasis the efficacy of butantrone was somewhat lower compared to dithranol. Butantrone has an antipsoriatic activity almost equal to that of dithranol. When short contact treatment is used, erythema and staining with butantrone are weaker than with dithranol. |
|
| DC74952 |
CFI-400437 HCl |
CFI-400437 is a potent and selective inhibitor of polo-like kinase 4 (PLK4). The family of Polo-like kinases is important in the regulation of mitotic progression; this work keys on one member, namely Polo-like kinase 4 (PLK4). PLK4 has been identified as a candidate anticancer target which prompted a search for potent and selective inhibitors of PLK4. |
|
| DC74953 |
DTP3 inhibitor |
DTP3 is a selective GADD45β/MKK7 inhibitor, which inhibits cancer-selective NF-κB survival pathway. DTP3 specifically kills MM cells, ex vivo and in vivo, ablating MM xenografts in mice, with no apparent adverse effects, nor evident toxicity to healthy cells. DTP3 combines on-target-selective pharmacology, therapeutic anticancer efficacy, favourable drug-like properties, long plasma half-life and good bioavailability, with no target-organs of toxicity and no adverse effects preclusive of its clinical development in oncology, upon daily repeat-dose administration in both rodent and non-rodent species. |
|
| DC74954 |
Nolatrexed HCl |
Nolatrexed, also known as AG337, is a thymidylate synthase inhibitor with potential anticancer activity. A phase II study of nolatrexed in 2007 in advanced HCC patients demonstrated minimal activity and significant stomatitis. Hence, it does not warrant further study as a single agent for this disease. |
|
| DC74955 |
PD159206 |
PD-159206 is a nucleocapsid inhibitor. It exhibits good antiviral activity against HIV. |
|
| DC74956 |
Dimethyl carbate |
Dimethyl carbate, also known as Dimalone, is an insect repellent. It can be prepared by the Diels–Alder reaction of dimethyl maleate and cyclopentadiene. |
|
| DC74957 |
Oxytocin acetate |
Oxytocin is a medication and hormone. As a medication, it is used to cause contraction of the uterus, which is used to start labor, increase the speed of labor, and to stop bleeding following delivery. It is used either by injection into a muscle or into a vein. Medical uses can result in excessive contraction of the uterus that can cause distress in an unborn baby. Common side effects in the mother include nausea and a slow heart rate. Oxytocin is normally produced in the hypothalamus and stored in the posterior pituitary gland. It plays a role in social bonding, sexual reproduction in both sexes, and during and after childbirth. It is released due to stretching of the cervix and uterus during labor and with stimulation of the nipples from breastfeeding. |
|
| DC74958 |
Democonazole |
Democonazole is an antimycotic agent. |
|
| DC74959 |
Levonorgestrel |
Levonorgestrel is a manufactured hormone used in a number of birth control methods. In pill form, it is useful within 120 hours as emergency birth control. It becomes less effective the longer after sex and only works before pregnancy has occurred. It is also combined with an estrogen to make combined oral birth control pill. Within an IUD, it is effective for long term prevention of pregnancy. An implantable form of levonorgestrel is also marketed in some countries. |
|
| DC74960 |
LY-2608204 |
LY-2608204 is an activator of glucokinase (GK) with an EC50 value of 42 nM. LY2608204 decreases plasma glucose in a dose-dependent manner at both fasted and postprandial glucose levels. In 2010, LY-2608204 was entered clinical trials in Patients With Type 2 Diabetes. |
|
| DC74961 |
KPI-10 |
KPI-10, also known as WQ3810, is a new compound currently being studied for its efficacy in the treatment of infections caused by multidrug-resistant bacteria. WQ-3810 demonstrated high potent activity against the antimicrobial-resistant pathogens tested. WQ-3810 (MIC(90)=4 mg/L and 0.06 mg/L, respectively) was also more active than ciprofloxacin (64 mg/L and 2 mg/L) and levofloxacin (32 mg/L and 2 mg/L). Furthermore, WQ-3810 was the most potent among the fluoroquinolones tested against meticillin-resistant Staphylococcus aureus (MRSA) and Neisseria gonorrhoeae, including FQR isolates. |
|
| DC74962 |
Carisbamate |
Carisbamate, also known as JNJ-10234094, RWJ 333369 and YKP-509, is an antiepileptic candidate. Carisbamate has powerful disease-modifying effects in the lithium-pilocarpine model of temporal lobe epilepsy. Carisbamate inhibits glutamate transmission in the granule cell of the dentate gyrus. Carisbamate acutely suppresses spasms in a rat model of symptomatic infantile spasms. |
|
| DC74963 |
Umifenovir HCl |
Umifenovir, also known as arbidol, is an antiviral treatment used in Russia and Chinafor influenza infection. Since 2005 it has been the number one best-selling over-the-counter drug in Russia. Umifenovir inhibits membrane fusion. Umifenovir prevents contact between the virus and target host cells. Fusion between the viral capsid and the cell membrane of the target cell is inhibited. This prevents viral entry to the target cell, and therefore protects it from infection. |
|
| DC74964 |
Pirtobrutinib |
Pirtobrutinib, also known as LOXO-305 and LY 3527727, is a Bruton's tyrosine kinase (BTK) inhibitor and antineoplastic agent. Pirtobrutinib showed promising initial efficacy in pts with pretreated Richter transformation with extremely poor prognosis, including in patients who had received prior chemoimmunotherapy and covalent BTK inhibitors. Pirtobrutinib is a highly selective and potent non-covalent BTK inhibitor (BTKi) with high oral bioavailability and a long half-life, resulting in robust BTK target coverage even in high-grade malignancies with high BTK protein turnover. |
|
| DC74965 |
Tiplasinin free acid |
Tiplaxtinin, also known as PAI-039, is a novel plasminogen activator inhibitor-1 (PAI-1) inhibitor. The pharmacokinetic profile of PAI-039 indicated an oral bioavailability of 43 +/- 15.3% and a plasma half-life of 6.2 +/- 1.3 h. PAI-039 is an orally active prothrombolytic drug that inhibits PAI-1 and accelerates fibrinolysis while maintaining normal coagulation in a model of coronary occlusion . PAI-039 exerts antithrombotic efficacy in rat models of arterial and venous vascular injury without effecting platelet aggregation. PAI-039 as a novel therapeutic may improve diabetic wound closure. |
|
| DC74966 |
Fabomotizole HCl |
Fabomotizole, also known as Afobazole, Obenoxazine and CM346, is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions. Its mechanism of action remains poorly defined however, with GABAergic, NGF- and BDNF-release-promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Fabomotizole was shown to inhibit MAO-A reversibly and there might be also some involvement with serotonin receptors. |
|
| DC74967 |
Fluoxetine HCl |
Fluoxetine, also known by trade names Prozac and Sarafem among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It may decrease the risk of suicide in those over the age of 65. Fluoxetine has also been used to treat premature ejaculation. It is taken by mouth. |
|
| DC74968 |
Tracazolate HCl |
Tracazolate is an allosteric modulator of GABAA receptors. Tracazolate interacts with gamma-aminobutyric acid (GABA)(A) receptors, adenosine receptors, and phosphodiesterases. |
|
| DC74969 |
Metaraminol Bitartrate |
Metaraminol bitartrate is a sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of hypotension. |
|
| DC74970 |
CC90001 free base |
CC-90001 is a potent and selective JNK inhibitor, which is 12.9-fold more potent for JNK1 inhibition than JNK2 in a cell-based model. CC90001 currently under clinical trials for the Treatment of Idiopathic Pulmonary Fibrosis. |
|
| DC74971 |
Cefotetan Sodium |
Cefotetan Sodium, also known as ICI-156834 and YM-09330, is a second-generation cephalosporin, cephamycin antibiotic that is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative bacteria. Cefotetan binds to penicillin-binding proteins and disrupts the cell wall synthesis. |
|
| DC74972 |
Exeporfinium bromide |
Exeporfinium, also known as XF-73, is an anti-microbial which works via weakening bacteria cell walls. Exeporfinium chloride is a potential treatment for methicillin-resistant Staphylococcus aureus (MRSA) and possibly Clostridium difficile. Exeporfinium chloride has completed a phase I clinical trial for nasal decolonisation of MRSA—being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it. Structurally it is a dicationic porphyrin. |
|
| DC74973 |
NADH |
NADH is the reduced form of NAD, or nicotinamide adenine dinucleotide. NADH is used as a reducing agent to donate electrons in metabolic reactions. |
|
| DC74974 |
Simufilamum |
Simufilamum, also known as PTI-125, is a filamin A altered conformations binder. PTI-125 is an oral small molecule drug candidate that binds and reverses an altered conformation of the scaffolding protein filamin A found in Alzheimer's disease brain. PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer's disease pathogenesis. PTI-125 also reduced tau hyperphosphorylation, aggregated Aβ42 deposition, neurofibrillary tangles, and neuroinflammation. Efficacy in postmortem AD and Aβ42-treated age-matched control hippocampal slices was concentration-dependent starting at 1 picomolar (pM) concentration. PTI-125 is the first therapeutic candidate to preferentially bind an altered protein conformation and reverse this proteopathy. |
|
